Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

IGCCCG Risk Classification

A metastatic germ cell tumor risk classification using histology, primary site, non-pulmonary visceral metastases, AFP, hCG, and LDH.

Evidence-based context for fast calculator use

Purpose:
Stratify prognosis and support first-line platinum-based chemotherapy planning.
Population:
Patients with metastatic seminoma or non-seminomatous germ cell tumors.
Factors:
Histology, Primary site, Non-pulmonary visceral metastases, AFP, hCG, LDH
Reference:
Beyer et al., J Clin Oncol. 2021.
HomeIGCCCG Risk Classification (2021 Update)
Pin your most used calculators here by clicking the star in the dropdown.

IGCCCG Risk Classification (2021 Update)

Clinical Context & Background

The International Germ Cell Cancer Collaborative Group (IGCCCG) classification stratifies metastatic non-seminoma and seminoma into good, intermediate, and poor risk groups using histology, primary site, metastatic pattern, and serum tumor markers.
Use IGCCCG when a patient has metastatic germ cell tumor and the question is first-line treatment intensity, prognosis counseling, trial stratification, or tumor board documentation. Pure seminoma has no poor-risk IGCCCG group; elevated AFP should prompt review for non-seminomatous elements or mixed germ cell tumor classification.
The 2021 update re-validated the original criteria with modern platinum-era outcomes and survival estimates.
Primary Source EvidenceBeyer J, Collette L, Sauvé N, et al. Survival and New Prognostic Factors in Metastatic Germ Cell Tumors in the Platinum-Based Chemotherapy Era: IGCCCG Update. J Clin Oncol. 2021;39(14):1556-1566.
Formula Logic
Risk based on Primary Site, Markers (AFP, hCG, LDH), and Mets location.

Reference Data

Risk Group5-Year Survival (2021 Update)Treatment (Standard)
Good Risk96% (Non-Sem) / 95% (Sem)BEP x 3 or EP x 4
Intermediate89% (Non-Sem) / 88% (Sem)BEP x 4
Poor Risk67% (Non-Sem)BEP x 4 or VIP x 4

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use for metastatic testicular or extragonadal germ cell tumors before first-line systemic therapy.
  • Best suited for prognosis counseling, chemotherapy-intensity planning, clinical trial stratification, and tumor board documentation.
  • Apply after histology, primary site, metastatic pattern, AFP, hCG, and LDH are confirmed.

How To Interpret

  • Good, intermediate, and poor risk groups map to different expected outcomes and commonly used platinum-based chemotherapy approaches.
  • Pure seminoma does not have a poor-risk IGCCCG category; non-pulmonary visceral metastases move seminoma to intermediate risk.
  • For non-seminoma, mediastinal primary, non-pulmonary visceral metastases, or S3 tumor markers place the patient in a poor-risk group.

What To Do Next

  • Verify tumor markers are pre-treatment or appropriately timed and interpreted with assay units and upper limits.
  • Review AFP elevation in a presumed seminoma because it can indicate non-seminomatous or mixed germ cell tumor biology.
  • Use the result to frame BEP/EP/VIP regimen discussion, fertility preservation, supportive care planning, and specialist referral urgency.

Limitations

  • Do not use for stage I surveillance-only decisions or post-salvage prognosis.
  • The score does not replace full staging, imaging review, pulmonary function assessment, renal function review, or cisplatin eligibility assessment.
  • Clinical decisions should follow contemporary germ cell tumor guidelines and multidisciplinary review.

Validated Population

Patients with metastatic seminoma or non-seminomatous germ cell tumors evaluated before first-line platinum-based chemotherapy.

Example use

A patient with non-seminomatous germ cell tumor, testicular primary, lung-only metastases, AFP under 1,000, hCG under 5,000, and LDH under 1.5 x ULN classifies as good risk; liver, bone, brain metastases, mediastinal primary, or S3 markers would shift the pathway.

MSKCC NSGCT nomogramUse as an adjacent non-seminomatous germ cell tumor prognostic tool.ECOG performance statusDocument functional status before systemic therapy planning.WHO performance statusCapture treatment fitness and trial eligibility context.

Share This Calculator

Share:

Related Tools

MSKCC Stage I NSGCT Nomogram

Frequently Asked Questions

When should IGCCCG be used?

Use IGCCCG for metastatic germ cell tumors before first-line systemic therapy, not for clinical stage I surveillance decisions.

Can pure seminoma be poor-risk by IGCCCG?

No. Pure seminoma is classified as good or intermediate risk by IGCCCG. Elevated AFP should prompt review for non-seminomatous or mixed germ cell tumor elements.

Evidence-based oncology decision support. Verify with clinical guidelines.